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Introduction
Tuberculous meningitis (TBM) is the second most common 
cause of adult meningitis in sub-Saharan Africa1,2, account-
ing for one to five percent of the 10.4 million tuberculosis (TB) 
cases reported worldwide in 20163. Despite treatment, TBM 
outcomes are poor with 19–28% mortality in HIV-uninfected 
persons and 40–67% mortality in HIV-infected patients in 
addition to long-term disability is frequent among survivors4–6.
Insidious symptom onset in persons with TBM leads to delay 
in seeking care and increasing disease severity at presentation 
correlates with higher mortality7. Further, the paucibacillary 
nature of TBM increases the difficulty in confirming diagno-
sis once care is sought, also contributing to high mortality8. 
Cerebrospinal fluid (CSF) smear microscopy for acid-fast bacilli 
(AFB smear) has poor sensitivity (~10–20%) in routine practice7. 
Culture has improved sensitivity (~50–60%) but is not widely 
available in many resource constrained settings and com-
monly takes at least 2–3 weeks for liquid culture growth, 
which is too slow to guide decision-making at the time of 
presentation8. 
In 2013, the World Health Organization endorsed the Xpert 
MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, California, USA), 
a cartridge-based, polymerase chain reaction assay with a run 
time of 113 minutes, as the preferred initial test to investigate 
TB meningitis on the basis of a meta-analysis of 13 studies9. 
Of the two major studies included in the meta-analysis, Patel 
and colleagues reported 67% sensitivity against microbiologi-
cally proven TBM and 36% against consensus clinical case 
definitions, while Nhu and colleagues showed 59% sensitiv-
ity against the same case definitions10–12. Additionally, use of 
a larger volume of centrifuged CSF improves sensitivity of 
Xpert10,13. Yet, inadequate negative predictive value means that 
a negative Xpert result has limited influence on clinical decision 
making14.
There is evidence that use of Xpert for diagnosis of pulmonary 
TB reduces diagnostic delay, increases the rate of same day treat-
ment, and decreases usage of empiric treatment15,16. However, 
for pulmonary TB, Xpert has not been shown to decrease 
mortality16–18. Yet, lessening diagnostic delay in persons with 
TBM may be more likely to lead to improved outcomes as 
compared to pulmonary TB given the high early mortality 
of TBM19. Whether routine use of Xpert for investigation of 
suspected TBM has made an impact on diagnosis or mortality 
has not yet been investigated.
Herein we describe TBM diagnosis and outcomes over a 




Uganda is a high burden HIV setting, with a prevalence is 6.2% 
among adults aged 15 to 64 years with an estimated 60% viral 
load suppression in 2017 among all HIV-infected adults20. Adults 
presenting with suspected meningitis (headache and neck stiffness 
+/- vomiting, fever, seizures, focal neurological deficits, or altered 
consciousness), to Mulago National Referral Hospital, Kampala, 
and Mbarara Regional Referral Hospital, were assessed for eligi-
bility for enrolment in two consecutive randomised clinical trials 
investigating cryptococcal meningitis. The first trial Cryptococcal 
Optimal Antiretroviral Timing (COAT) investigated early versus 
delayed antiretroviral therapy in HIV-related cryptococcal men-
ingitis (www.clinicaltrials.gov: NCT01075152) and the second, 
Adjunctive Sertraline for the Treatment of Cryptococcal Menin-
gitis (ASTRO-CM) evaluated whether sertraline when added to 
standard amphotericin-based therapy for cryptococcal meningi-
tis, lead to improved survival (NCT01802385). Screening began 
on 22nd November 2010 and continued until 28th May 2017. After 
an informed consent process for trial screening a diagnostic 
lumbar puncture was performed and baseline demographics 
and clinical information were recorded on all. Participants with 
non-cryptococcal meningitis were not enrolled into the clinical 
trials but followed until hospital discharge. 
Any patient who received testing for TBM (CSF AFB smear, Xpert 
or mycobacterial culture) during this period was eligible to be 
included in the diagnostic accuracy analysis. Any patient who was 
ultimately treated for TBM was eligible to be included in one of 
the three TBM cohorts, from which data as used to compare rates 
of microbiological confirmation and outcomes. Cohort was deter-
mined by what type of TB testing they individual had undergone.
            Amendments from Version 1
Title
The title has been changed to: Tuberculous meningitis diagnosis 
and outcomes during the Xpert MTB/Rif era: a 6.5-year 
retrospective cohort study in Uganda
Methods:
As per reviewer suggestions we have expanded on the nature of 
the parent trials. To clarify who was eligible to be included in the 
diagnostic analysis and TBM cohort (n=195) we have added to 
the methods that “any patient from the 1672 patients screened 
who received testing for TBM (AFB smear, Xpert or culture) was 
eligible to be included in the diagnostic analysis and any patient 
who was treated for TBM was eligible to be included in the TBM 
cohort”. 
We have added a 2x2 table and a study schematic to make the 
flow of patients clearer as per the suggestion of Dr Wasserman 
and Dr Davis. It is not a classic Consort diagram as this 
population were not enrolled into a clinical trial. 
We have added a detail to the methods section to define empiric 
TBM treatment “TBM treatment given in the absence of a positive 
microbiologic result, based on a high index of clinical suspicion, 
was defined as ‘empiric TBM treatment’”.
Results
The reviewers kindly pointed out a typographical error in the 
manuscript. The number of microbiologically confirmed cases is 
74 (not 76) and the text has been amended accordingly. 
Regarding the sensitivity of Xpert and Ultra against a composite 
reference standard a 2x2 table has been added to accompany 
Figure 2. 
Discussion
In light of all three reviewer’s comments we have expanded the 
discussion to further acknowledge the other potential confounding 
factors and concluding that it is not possible to draw a conclusion 
about whether Xpert has reduced TBM mortality in this setting.
See referee reports
REVISED
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Figure 1. Timeline illustrating evolution of diagnostic testing.
Microbiologically proven (definite) TB meningitis was defined as 
any positive AFB smear, culture or Xpert result from CSF test-
ing. TBM treatment given in the absence of a positive microbio-
logic result, due to high index of clinical suspicion, was defined 
as ‘empiric TBM treatment’. Consensus uniform case definitions 
were used to categorise patients as definite, probable, possible or 
not TBM11. TBM treatment included 12 months of antitubercu-
lous therapy with 6–8 weeks of adjunctive corticosteroids as per 
Ugandan guidelines21. 
Cohort definitions and diagnostic tests used
Cohort one (16th November 2010 until 28th May 2013) received 
only CSF AFB smear testing (Figure 1). If available, 1mL 
cryopreserved CSF was later tested with Xpert MTB/Rif 
when Xpert became available. Cohort two (1st April 2011 until 
10th November 2013) underwent CSF AFB smear and Xpert 
MTB/Rif on a 1ml sample of uncentrifuged CSF. Testing was 
performed at physician discretion when there was lymphocytic 
pleocytosis and/or high degree of clinical suspicion. In the 
period of overlap of cohort one and two (April 2011–May 2013), 
Xpert testing was not being done on a routine basis; subjects 
were included in cohort two when Xpert was done in real-time 
and in cohort one if Xpert was not done, or only done at a 
later date on cryopreserved specimens.
In cohort three (11th November 2013 until 28th May 2017) all 
cryptococcal antigen negative (IMMY, Norman, Oklahoma, 
USA) patients were systematically investigated for the pres-
ence of TB meningitis, irrespective of physician discretion. 
Subjects had comprehensive testing for TBM with CSF AFB 
smear (Mulago Hospital only), Xpert MTB/Rif on large volume 
centrifuged CSF13 and CSF Mycobacteria Growth Inhibitor Tube 
culture (MGIT, Becton Dickinson, Franklin Lakes, USA). AFB 
smear was discontinued in Mbarara in 2013 as the sensitivity 
was deemed too low to justify further use. In patients with a 
confirmed diagnosis of cryptococcal meningitis (CM), if TBM 
co-infection was suspected, patients would be investigated 
for TBM at the physician’s discretion. 
Assessment of outcome
In-hospital outcome was determined from case report forms, 
hospital medical records or follow-up telephone calls with the 
patient or their surrogate where hospital outcome was unknown. 
The outcome was categorised as discharged alive, deceased prior 
to hospital discharge or unknown (i.e. self-discharged against 
medical advice in an imminently terminal patient, hospital 
outcome undetermined, transferred to another facility).
Statistical methods
Comparisons of categorical and continuous demographic and 
clinical characteristics by cohort were performed using Fisher’s 
exact tests and Kruskal-Wallis tests, respectively. Sensitivity 
of Xpert MTB/Rif was evaluated against a composite reference 
standard (any positive CSF test - AFB smear, Xpert or culture 
i.e. definite TBM according to the uniform case definition)11. 
A separate analysis was conducted against the uniform case 
definition of probable or definite TBM11. Concordance between 
Xpert MTB/Rif and culture was evaluated with a kappa 
statistic and McNemar’s test. Invalid tests (e.g. culture 
contamination, Xpert error) were counted as negative results. 
Mortality was first compared by cohort for participants with a 
known outcome using Fisher’s exact test. Data for patients with 
unknown outcome was imputed to assume first that 50% within 
each cohort died, or that 75% died (both within the expected 
mortality range for this population). Odds ratios and 95% 
confidence intervals were computed from multivariable logistic 
regression models with these imputed data, adjusted for 
1) ART status, and 2) ART status and definite TBM diagnosis. 
Imputations were repeated with new random assignments to 
confirm results. Analyses were conducted using SAS version 
9.4 (The SAS Institute, Cary, NC) and p-values <0.05 were 
considered statistically significant.
Ethics
Institutional review board approvals for the studies and the 
associated screening process were obtained locally in Uganda 
[ASTRO: Mulago Hospital Research Ethics Committee (approval 
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number, MREC 429); COAT: Makerere University School of 
Medicine Research and Ethics Committee (approval number, REC 
Ref No. 2009–022)], from the University of Minnesota (USA), 
and by the Uganda National Council of Science and Technology. 
Written informed consent for screening or participation in the 
studies was obtained from all participants or from their surrogates 
(e.g. family member or guardian) where the patient had altered 
mental status and did not have the capacity to provide consent.
Results
Participant characteristics
Over the study period, 1672 patients with meningitis symptoms 
were assessed and underwent lumbar puncture: 1058 (63%) had 
a positive CSF cryptococcal antigen test, 558 (33%) had nega-
tive CSF cryptococcal antigen test (data missing, n=56). A total 
of 195 subjects were treated for TBM, see Figure 2. Overall 61% 
were male, median age was 35 years (IQR 30–42), 96% were 
HIV-positive, median CD4 count was 78 cells/μL (IQR 26–191) 
and the majority (69%) presented with British Medical 
Research Council severity grade II disease, see Table 1. Base-
line characteristics were similar between cohorts with the 
exception of antiretroviral (ART) experience; 0% of participants 
were on ART in cohort one compared to 61% in cohort three 
(P<0.01).
Among the 74 cases of microbiologically proven TBM in this 
population with advanced HIV infection, 34% (25/74) had an 
acellular CSF (white cells <5 cells/μL) at presentation, and 
4% (3/74) had a normal CSF profile (CSF cells <5 cells/μL, 
protein <45 mg/dL, and glucose >2.2mmol/l).
Method of diagnosis
Microbiological confirmation of TBM was made in 38% 
(74/195) of cases. The proportion of cases with microbiologi-
cally confirmed TBM (definite TBM) increased significantly, 
from 3% (1/33) in cohort one to 87% (13/15) in cohort 2 and 
41% (60/147) in cohort 3 (P<0.01). Categorisation by uniform 
case definition is summarised in Table 2.
There was a marked difference in physician threshold for 
empiric TBM therapy between the two clinical sites. In cohort 
three, Mulago Hospital recorded 44 cases of which 77% (34/44) 
were microbiologically confirmed and 23% (10/44) were 
empirically treated, whilst Mbarara Hospital recorded 103 
cases of which 25% (26/103) were microbiologically confirmed 
and 75% (77/103) were empirically treated.
Diagnostic accuracy of Xpert MTB/Rif
Xpert MTB/Rif was positive in 51 of 455 tested (11%), 
MGIT culture positive in 39 of 321 (12%) tested, AFB 
stain positive on 5 of 818 tested (1%), as summarised in 
Table 2.
Diagnostic accuracy of Xpert and MGIT were analysed in 
cohort three, when both assays were done routinely, and 60 par-
ticipants had a microbiologically confirmed diagnosis (compos-
ite reference standard). Sensitivity of Xpert was 63% (38/60) 
against the composite reference standard and 54% (38/71) against 
the uniform case definition (probable or definite TBM). Sensi-
tivity of MGIT culture was 65% (39/60) against the composite 
reference standard of definite microbiologic-confirmed TBM 
Figure 2. Illustration of flow of patients from the screening population into the TBM cohort.
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N in TBM case cohort 33 15 147 195
Demographics
Sex 195 0.58
      Male 18 (55%) 8 (53%) 92 (63%) 118 (61%)
Age 195 0.33
      Median (IQR) 33 (29, 38) 35 (29, 40) 35 (30, 43) 35 (30, 43)
HIV details
HIV status, n (%) 195 1.00
      HIV-positive 32 (97%) 15 (100%) 141 (96%) 188 (96%)
ART status, n (%) 179 <0.01
      On ART 0 (0%) 4 (27%) 80 (61%) 84 (47%)
      ART naive 32 (100%) 11 (73%) 52 (39%) 95 (53%)
CD4 131 0.30




      I 9 (27%) 4 (31%) 20 (14%) 33 (17%)
      II 22 (67%) 7 (54%) 102 (70%) 131 (69%)
      III 2 (6%) 2 (15%) 23 (16%) 27 (14%)
*P-values from Fisher’s exact tests for categorical variables and Kruskal-Wallis tests for continuous variables.
and 55% (39/71) against uniform case definition for probable or 
definite TBM.
Concordance between Xpert MTB/Rif and MGIT culture was 
analysed in the 118 with both Xpert and MGIT culture results 
available (Table 3). Either Xpert or MGIT culture was positive 
in 56 patients, of which only 30% (17/56) were positive by both 
modalities (kappa 0.23 95% CI [0.04, 0.41], p=0.01) (Figure 3). 
Neither method diagnosed significantly more cases than the other 
(p=0.42). 
Outcomes
Hospital outcome was known for 142 participants, 53 had 
unknown outcomes or self-discharged against medical advice. 
Median time to death was 3 days (IQR 1–9 days) among those 
known to have died, and median length of hospitalization was 7 
days (IQR 4–10 days) for participants known to have survived 
to hospital discharge. Among those with known outcomes, there 
was a non-significant decline in mortality from 57% in cohort 
one to 41% in cohort three (p=0.27) (Table 4). Assuming that 
50% of those with unknown outcome died, and adjusting for 
ART status and definite TBM diagnosis at hospitalization, the 
odds of dying were approximately twice as high for cohort 
one (aOR 1.7 95% CI [0.7, 4.4]) and cohort two (1.8 [0.6, 5.6]) 
as compared to cohort three. Assuming that 75% of those with 
unknown outcome died, adjusted odds of death increase fur-
ther, cohort one (4.0 [1.5, 10.9]) and cohort two (2.0 [0.6,6.7]) 
compared to cohort three (Table 4, Figure 4).
Discussion
Rapid molecular diagnostics have been predicted to reduce TB-
related mortality22 but little is reported about the impact of Xpert 
on TBM-related mortality. Here we report diagnosis and clinical 
outcomes among hospitalized Ugandans treated for TB menin-
gitis over a 6.5-year period. In-hospital mortality was high in the 
cohort overall (44% 95% CI [36,52%]), similar to other research 
settings with high HIV prevalence7,19,23,24. The adjusted 
model found that odds of in-hospital mortality were almost 
two-fold higher in the earliest cohort, tested by CSF smear micro-
scopy only, compared to that of the most recent cohort in which 
Xpert (and culture) were routinely performed. Though severity 
of TBM at presentation was similar over the study period 
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Total number 471 71 1130 1672
    Cryptococcal Antigen positive 269 31 758 1058
    Cryptococcal Antigen negative 187 38 333 558
TBM diagnostic tests performed
CSF AFB smear microscopy*
    N AFB performed 466 71 281 818
    N AFB positive 1 (0%) 0 (0%) 4 (2%) 5 (1%)
CSF TB culture
    N TB culture performed 0 0 321 321
    N TB culture positive 0 0 39 (12%) 39 (12%)
CSF Xpert MTB/Rif
    N Xpert performed (realtime) 0 71 384 455
    N Xpert positive 0 13 (18%) 38 (10%) 51 (11%)
Uniform case definition
    Definite 1 (3%) 13 (87%) 60 (41%) 74 (38%) <.01
    Probable 5 (15%) 2 (13%) 11 (7%) 18 (9%)
    Possible 22 (67%) 0 (0%) 53 (36%) 75 (38%)
    Not 5 (15%) 0 (0%) 23 (16%) 28 (14%)
Prior to November, 2013 any patient not prospectively tested with Xpert was considered in Cohort 1 *AFB smear 
was initially performed on all meningitis patients regardless of CSF Cryptococcal antigen result. From October 
2013, it was only performed on those with a negative Cryptococcal antigen, and was later stopped altogether in 







positive 17 22 39
negative 17 62 79
Total 34 84 118
P-value from McNemar’s test
N=118 (with both Xpert and culture results)
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Figure 3. Venn diagram Illustrating the overlap of positive MGIT culture and Xpert test results in the n=118 samples tested with both 
assays. A total of 118 adults were tested with both MGIT culture and Xpert, of which 22 were positive by MGIT culture, 17 by Xpert and 17 by 
both tests. Neither test performed better than the other, p=0.423 by McNemar’s. A kappa statistics value of 0.23 95%CI [0.04, 0.41], p=0.01, 

















N in TBM case cohort 33 15 147 195
Outcome of hospitalization
   Unknown 26 (79%) 4 (27%) 23 (16%) 53 (27%)
   Known 7 (21%) 11 (73%) 124 (84%) 142 (73%)
      Discharged Alive 3 (43%) 4 (36%) 73 (59%) 80 (56%) 0.27
      Died 4 (57%) 7 (64%) 51 (41%) 62 (44%)
Odds Ratio (Mortality) and 95% CI (on imputed data)
   Assuming 50% of unknowns died
      Adjusted for ART status 1.5 (0.6,3.6) 2.0 (0.7,6.2) 1
       Adjusted for ART status and 
confirmed TBM
1.7 (0.7,4.4) 1.8 (0.6,5.6) 1
   Assuming 75% of unknowns died
      Adjusted for ART status 3.3 (1.3,8.4) 2.5 (0.8,7.8) 1
       Adjusted for ART status and 
confirmed TBM
4.0 (1.5,10.9) 2.0 (0.6,6.7) 1
Overall median (IQR) time in hospital was 7 (4, 10) days among those who were known to be discharged alive, 
and 3 (1, 9) days among those who were known to have died in hospital
*P-value from Fisher’s exact test comparing KNOWN discharged alive vs KNOWN died; Odds ratios are the odds 
of being discharged alive, assuming 50% and 75% of those with unknown outcome died
and TBM treatment recommendations have not changed for 
Uganda, there are multiple other potential confounding fac-
tors due to the nature of the study. Improved access to ART, 
strengthening in healthcare services, increased awareness of TBM 
amongst communities and healthcare workers or changes in 
employment of empiric treatment all may have occurred over the 
study period and if present, may have impacted our findings. Due 
to these potential confounding factors, it is not possible to draw 
a conclusion about whether Xpert has reduced TBM mortality in 
this setting.
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The proportion of ART experienced subjects increased 
significantly over time with improved access to ART treatment in 
Uganda and because the parent trial in cohort one enrolled only 
ART naïve subjects25. Although ART status was not associated 
with mortality, we adjusted for ART in multivariable models due 
to the large discrepancy in ART status between cohorts. 
Nonetheless the impact of ART use is likely to have played 
a role in the observed decline in mortality.
Despite a non-significant decline in mortality, a current case- 
fatality rate of 41% remains unacceptably high and highlights 
the remaining work required to achieve the WHO goal of reduc-
ing TB-related deaths by 90% by 203026. Initiating treatment 
in the early stage of disease is the single most important factor 
in improving outcomes7. Earlier presentation to the hospital is 
essential for prompt diagnosis and treatment initiation, yet, 83% 
of our cohort presented with MRC grade II or III disease.
Once the patient presents to care, an affordable, rapid, and reli-
able test that can effectively confirm or rule out TBM is crucial 
for prompt diagnosis. In this predominantly HIV-positive TBM 
cohort, sensitivity of Xpert was 63% against the composite 
reference standard. Thus, even though results were available 
rapidly, Xpert missed over one in three cases. The next gen-
eration assay Xpert MTB/Rif Ultra has an analytic limit of 
detection of 15 colony forming units (CFU)/ml, compared to 
113 CFU/ml for Xpert27. Ultra appears to be significantly more 
sensitive than Xpert or culture for the diagnosis of TBM (95% 
Figure 4. Illustration of odds of dying in cohort one and two compared to cohort three in a multivariate model. Odds ratios (and 95% 
confidence intervals) for death by the end of hospitalization comparing cohorts 1 and 2 to cohort 3, computed from multivariable logistic 
regression models with imputed data, adjusted for (1) ART status, and (2) ART status and definite TBM diagnosis. Data for patients with 
unknown outcome was imputed to assume that 50% within each cohort died, or that 75% died. In all models, neither ART nor definite TBM 
status had a significant association with in-hospital mortality, adjusted for cohort.
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versus 45% and 45% respectively, P<0.001)28. Whether Ultra 
can reduce diagnostic delay and improve outcome from TBM 
requires further prospective evaluation.
Where both Xpert and MGIT had been done, less than a third 
(23%, 17/74) of confirmed cases were positive by both modali-
ties. This is consistent with prior findings and is likely due to the 
relatively higher sensitivity of culture versus Xpert, and the ability 
of Xpert to detect non-viable TB bacilli damaged by host-immune 
response and/or antituberculous drug therapy13,28. Neither test 
performed better than the other (P=0.42) and currently CSF culture 
continues to earn a place in TBM diagnostics testing algorithms.
Until a rapid test with suitable negative predictive value is widely 
available, there is likely to be on-going heterogeneity in clinical 
practice regarding frequency of empiric TBM therapy (TB treat-
ment in the absence of a positive result). Here, Mulago Hos-
pital participants were treated for TBM on an empiric basis in 
under one quarter of cases as opposed to over three quarters 
of cases at Mbarara Hospital, despite the same diagnostic arma-
mentarium being available in both settings. In our study settings, 
it is likely that individual or departmental clinical practice and 
risk thresholds for TB treatment initiation dictate this variation. 
Though empiric TBM therapy is potentially life-saving, signifi-
cant risks such as side effects, drug-interactions and adjunctive 
steroids in an already immunosuppressed population need to 
be considered. Ideally, a rapid, accurate test allows therapy for 
TB meningitis to be started promptly only in those who actually 
have TBM. Overall, the proportion with microbiologically con-
firmed TBM increased significantly from 3% in cohort one to 
41% in cohort three (P<0.01). In cohort two, selection bias could 
have impacted on results as Xpert was only performed in cases 
where there was extremely high index of suspicion and empiric 
treatment was given only twice in those with a negative Xpert 
(4%, 2/56). The low number of empiric diagnoses during this 
period were likely due to over-confidence in Xpert’s ability to 
rule-out TBM. As understanding regarding the limitations of 
Xpert for the diagnosis of TBM became known, empiric TBM 
treatment rose14.
Limitations of this study relate to the nature of available data 
namely missing data on hospital and long-term outcomes, the 
time to starting TB treatment, unbalanced numbers in each cohort, 
and other un-adjusted confounding factors and potential 
sources of bias. When imputing data in the model we assumed 
that either 50% or 75% of patients with unknown outcome 
actually died, which is a clinically reasonable judgment for this 
population4.
Here we present important data on diagnostic confirmation 
and TBM mortality during a period of TB diagnostic evo-
lution. There has been a significant increase in microbio-
logical confirmation and a modest, albeit non-significant, 
decline in mortality since introduction of Xpert and culture in 
our study setting. An on-going multifaceted approach is needed 
to further reduce death and disability from TBM.
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1. The study design is unclear: is this a retrospective or post-hoc analysis of data




2. The denominator is not clearly reported: the inclusion criteria for the current analysis
appears to be “all meningitis suspects with a negative CSF cryptococcal antigen.” Were
558 patients with negative CSF cryptococcal antigen test included in the analysis?
The main analysis for microbiological confirmation and mortality relates to the 195 people within
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3. The conclusion that “in-hospital mortality has declined” seems exaggerated because
this trend towards lower mortality over the study periods was not significant, and may
















2. Differences between the cohorts could have introduced bias
This is a valid observation. Text stating "selection bias could have impacted on results" has been
added to the discussion. 
3. Please explain how the performance of a test (eg Xpert) can be compared to a reference








4. Were the variables in the multivariate model selected ?a priori
Yes
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1. The denominator is not clearly reported: the inclusion criteria for the current analysis
appears to be “all meningitis suspects with a negative CSF cryptococcal antigen.” Were
558 patients with negative CSF cryptococcal antigen test included in the analysis, or was
it 195 subjects that were treated for TBM? This should match the inclusion criteria, which
appear to be any patient with suspected meningitis and negative CrAg testing.
I hope the response to comment on abstract has clarified this. 
2. A large proportion of patients in cohorts 2 and 3 were on ART at the time of
presentation: this could alter their prognosis and bias the results. Although the model
adjusted for this, it should be emphasised more in the discussion.
This has been emphasised in the discussion of the revised manuscript. 
3. There is a discrepancy in the number of microbiologically proven cases
Thanks for spotting this typo. This has been corrected to 74. 
4. Why was the number of confirmed cases so high in Cohort 2
The review by Dr Hamers also made this comment. Please see response to his comment for a
potential explanation. 
5. The paragraph describing empiric treatment practices requires clarification: how was
‘empiric treatment’ defined? The numbers appear to suggest that no patients with a
confirmed diagnosis were empirically treated (ie empiric treatment = no microbiological
confirmation). Suggest changing the terminology to make this clearer. 
Thank you. We have defined this more clearly in the methods. 
6. So, the important question seems to be why there was such a big discrepancy in the
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8. Suggest including a 2 x 2 table to demonstrate the performance of diagnostic tests.
We have added a 2x2 table. 
Discussion
1. The main (and probably only data-driven) conclusion is that more confirmed TBM cases
were detected with the use of Xpert and culture. The authors did not convincingly show an
improvement in outcomes. Any observed trends could be secular, or related to other




2. For example the use of imaging diagnostics, time to treatment, availability of drugs,
better understanding of supportive measures in TBM. I feel that these should form part of
the discussion here and although they may not be quantifiable in this setting, should be
acknowledged as possible factors for the observed differences over time. In this setting
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1. The title suggests that the aim of the study was to investigate if better TBM diagnostics




2. Indeed, many other factors could have influenced the differential outcomes across the 3
historical cohorts that span the time period of 2011-2017, and I feel the authors could





3. The authors have (deliberately) done separate analyses on the 3 cohorts, and
combining historical cohorts may have its limitations. Nonetheless, the combined cohort
offers opportunities to attempt answering the main question. In this respect, it would be
interesting if the authors could undertake a multivariate analysis of the combined cohort
data to identify what are the main determinants of mortality (adjusting for time period).
This could help to establish whether indeed the diagnostics influenced outcomes, or that
the survival gain was mainly driven by other factors (e.g. ART). In my view, adding this
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 the survival gain was mainly driven by other factors (e.g. ART). In my view, adding this














4. The % of microbiological confirmation is 3% in cohort #1, 87% in cohort #2, and 41% in
cohort #3. It would be relevant to learn why the latest % seems to be lower than the middle










5. The degree of agreement between Xpert and MGIT is very low (kappa 0.23). I would like
to see a better explanation for this discrepancy, and how this knowledge can to be applied
in recommendations for testing algorithms in practice.
This is another interesting observation, and a somewhat surprising finding to us also. We have not
elaborated in the discussion in the interest of brevity but possible explanations are mentioned here:








Positive on culture whilst negative on Xpert:
Culture has a lower limit of detection that Xpert so patients with bacillary burdens on the
<100CFU/ml region would likely be identified by culture only. 
Considerations for future testing algorithms:
It is hopeful that the next generation assay Xpert MTB/Rif 'Ultra' will have a limit of detection similar
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1. The findings provide limited evidence that improved diagnostics have improved
outcomes of TBM in this cohort and due to the observational design are likely to be
influenced by numerous unmeasured confounding factors. I think that this well written
work definitely deserves to be published but feel that the conclusions should reflect a







2. Part of the work-up of a patient with suspected TBM is a search for extra-neural TB and
we do not know how this changed over time although it is likely that Xpert MTB/RIF was





3. It must be remembered that new diagnostics also have the potential to worsen
outcomes, particularly if clinicians miss-interpret negative tests as ruling out the
condition as might well occur with Xpert MTB/RIF and TBM.
I completely agree. The delay in waiting for a diagnostic test result must also be recognised, which
can be several days in many hospital settings. Bring on an accurate bedside POCT. 
4. The abstract says that all 1672 patients were HIV infected but in the results section is
says 96% were HIV infected so there is a discrepancy.
Thanks for pointing out this oversight. I have added the word predominantly to the abstract. 
5. Last line, para 1 of introduction, probably remove word ‘to’.
Well spotted. Thank you. 
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 Well spotted. Thank you. 
6. Last line. Para 3 of introduction- It is not that Xpert cannot substitute for clinical
judgement- Xpert is used to enhance clinical judgement, it’s just that the  poor sensitivity
 means that when negative it has limited influence on decision making.
The text of the revised manuscript has been changes to read "a negative Xpert result has limited
influence on clinical decision making". 
7. Statistical methods- the uniform case definition is probable or definite TBM- do the
authors think this is a reasonable reference standard for other tests? My view is that the
threshold for treating TBM is very low and that patients with possible/probably or definite
TBM should receive treatment and therefore this would be a more appropriate reference









8. Methods- Not clear if there were 76 or 74 microbiologically proven cases
Thanks for pointing out this typo. The test has been corrected to 74. 
9. Discussion- Para 1, repeat of ‘that of’
Well spotted again. Thank you. 
10. Discussion- Para 4, First sentence implies that tests are the only answer to the
diagnosis of TBM, what about clinical prediction rules relying on clinical data- although so
far they have not been very successful, neither have tests so a robust CPR may negate




Discussion- Para5, Do the authors really think there are dead bacilli in CSF? Some of the
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 Thanks again for your comments. We hope the revised manuscript is to your satisfaction. 
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